Paeciloquinone F
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Enzyme inhibitors |
| Catalog number | BBF-02345 |
| CAS | 162797-37-7 |
| Molecular Weight | 398.32 |
| Molecular Formula | C20H14O9 |
Online Inquiry
Description
It is produced by the strain of Paecilomyces carneus P-177. It can inhibit the epidermal growth factor receptor protein tyrosine kinase.
Specification
| Synonyms | 2,5-Epoxyanthra[2,3-b]oxepin-5(2H)-carboxylic acid, 3,4,7,12-tetrahydro-6,8,10-trihydroxy-2-methyl-7,12-dioxo-, (1S,17R)- |
| IUPAC Name | (1S,17R)-3,7,9-trihydroxy-17-methyl-5,12-dioxo-16,20-dioxapentacyclo[15.2.1.02,15.04,13.06,11]icosa-2(15),3,6(11),7,9,13-hexaene-1-carboxylic acid |
| Canonical SMILES | CC12CCC(O1)(C3=C(O2)C=C4C(=C3O)C(=O)C5=C(C4=O)C=C(C=C5O)O)C(=O)O |
| InChI | InChI=1S/C20H14O9/c1-19-2-3-20(29-19,18(26)27)14-11(28-19)6-9-13(17(14)25)16(24)12-8(15(9)23)4-7(21)5-10(12)22/h4-6,21-22,25H,2-3H2,1H3,(H,26,27)/t19-,20+/m1/s1 |
| InChI Key | VFXZFYHLJCNYMX-UXHICEINSA-N |
Properties
| Appearance | Yellow Crystal |
| Melting Point | 201-205°C |
| Solubility | Soluble in Chloroform, Ethanol |
Reference Reading
1. Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study
Youcai Li, Xinqing Lin, Yi Li, Jie Lv, Peng Hou, Shaoyu Liu, Penghao Chen, Min Wang, Chengzhi Zhou, Xinlu Wang Mol Imaging Biol. 2022 Apr;24(2):309-320. doi: 10.1007/s11307-021-01679-w. Epub 2021 Nov 23.
Purpose: The purpose of this study was to compare the primary staging of F-18 labeled fibroblast activation protein inhibitor ([18F]F-FAPI) with that of F-18 labeled fluordesoxyglucose positron emission tomography/computed tomography ([18F]F-FDG PET/CT) in patients with lung adenocarcinoma (LAD). Procedures: We prospectively analyzed the images of LAD patients who underwent [18F]F-FAPI and [18F]F-FDG PET/CT between May 2020 and August 2021. [18F]F-FAPI and [18F]F-FDG uptakes were compared using the paired samples t test, and lesion numbers were compared using the Wilcoxon signed-rank test. Results: Thirty-four LAD patients were evaluated. Patients showed high [18F]F-FAPI uptake in primary lesions (SUVmax 12.54 ± 3.77). Both [18F]F-FAPI and [18F]F-FDG had 100% detection rates for primary tumors. However, [18F]F-FAPI showed higher SUVmax than [18F]F-FDG in lesions of the lymph nodes, pleura, bones, and other tissues (all P ≤ 0.05). Although the absolute uptake values of [18F]F-FAPI in brain lesions were lower than those of [18F]F-FDG (1.56 ± 2.19 vs.7.34 ± 3.54, P < 0.0001), the tumor-to-background (T/B) ratios were significantly higher than those of [18F]F-FDG (9.53 ± 12.07 vs.1.01 ± 0.49, P < 0.0001). Generally, [18F]F-FAPI PET/CT could visualize more total lesions than [18F]F-FDG (554 vs.464, P = 0.003), especially in lymph nodes (258 vs.229, P = 0.039), the brain (34 vs.9, P = 0.002), and pleura (56 vs.30, P = 0.041). However, contrast-enhanced brain magnetic-resonance imaging (MRI) showed more brain lesions than [18F]F-FAPI PET/CT (56 vs.34, P = 0.002). Compared with the [18F]F-FDG-based TNM stage, the [18F]F-FAPI-based TNM stage was upgraded in six patients (17.6%). Conclusions: [18F]F-FAPI PET/CT showed a very high detection rate for primary LAD. In addition, 18F-FAPI PET/CT demonstrated clearer tumor delineation and more lesions than [18F]F-FDG PET/CT, especially in lymph nodes, the brain, and pleura. Therefore, [18F]F-FAPI had an advantage over [18F]F-FDG for primary staging of LAD. However, brain MRI could identify more and smaller lesions than [18F]F-FAPI PET/CT.
2. Radiosynthesis of 18F-fluoroethylated tracers via a simplified one-pot 18F-fluoroethylation method using [18F]fluoroethyl tosylate
Kazunori Kawamura, Katsushi Kumata, Wakana Mori, Masayuki Fujinaga, Yusuke Kurihara, Masanao Ogawa, Takayuki Ohkubo, Kenji Furutsuka, Hiroki Hashimoto, Nobuki Nengaki, Ming-Rong Zhang Appl Radiat Isot. 2021 Mar;169:109571. doi: 10.1016/j.apradiso.2020.109571. Epub 2020 Dec 26.
Recently, a straightforward one-pot method for 18F-fluoroethylation without azeotropic drying of cyclotron-produced [18F]F- was developed. In this study, we have attempted to simplify the automated radiosynthesis of two [18F]fluoroethylated tracers, [18F]FEDAC and [18F]FET, using a desmethyl labeling precursor and [18F]fluoroethyl tosylate, based on the above-mentioned method. The radiochemical yields of [18F]FEDAC and [18F]FET were 26 ± 3.7% (n = 5) and 14 ± 2.2% (n = 4), respectively, based on total [18F]F- at the end of irradiation.
3. Determination of human FaFg of polyphenols using allometric scaling
Takuya Kikuchi, Shunta Shigemura, Yuichi Ito, Kazutoshi Saito J Toxicol Sci. 2022;47(10):409-420. doi: 10.2131/jts.47.409.
Certain polyphenols exhibit low permeability; precise prediction of their intestinal absorption is important for understanding internal exposure in humans. Intestinal availability, which represents the fraction of administered compounds that reach the portal blood (FaFg), is calculated by dividing bioavailability (F) by hepatic availability (Fh), and F is obtained from pharmacokinetic data from both intravenous (i.v.) and oral (p.o.) administration. However, human FaFg of polyphenols is hardly reported, as human i.v. data are extremely scarce. In this study, we developed an estimation method for FaFg of polyphenols in humans based on the extrapolation of rat clearance using allometric scaling (allometric scaling-based FaFg calculation method, AS- FaFgCM). First, for quercetin, for which human i.v. data have been reported, we compared the FaFg obtained by AS-FaFgCM with the traditional approach using human i.v. and p.o. data. Less than two-fold difference in FaFg values was observed between the two approaches. Next, we obtained FaFg of structurally diverse polyphenols (genistein, baicalein, resveratrol, and epicatechin) using AS-FaFgCM, demonstrating that all of them were poorly absorbable. Furthermore, to utilize the pharmacokinetic data of the total concentration, including aglycones and metabolites, we modified the AS-FaFgCM to focus on their excretion. The FaFg value of naringenin was obtained using modified AS-FaFgCM and was nearly equal to that of baicalein, a structural isomer of naringenin. This study provides quantitative information on the intestinal absorption of polyphenols using comprehensive estimation methods.
Recommended Products
| BBF-05862 | Epirubicin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
